Axonyx to 3rd Annual Global Healthcare Conference.
Alzheimer's Donation
Donate Online Now
.
The presentation will be Web cast live via streaming audio and canbe accessed by visiting the Axonyx Web site at www.axonyx.com. Forthose unable to listen to the live Web cast, a replay of thepresentation will be available for 30 days on the Company's Web site. Partiesinterested in scheduling 1-on-1 meetings with Dr. Bruinsma are invitedto contact Lily Khaykina at LK@rodmanandrenshaw.com.
About Axonyx
Axonyx Inc. is a U.S.-based biopharmaceutical company engaged inthe acquisition and development of proprietary pharmaceuticalcompounds for the treatment of Central Nervous System disorders. TheCompany currently has three compounds in development for Alzheimer'sdisease; Phenserine - a potential symptomatic and disease progressiontreatment of mild to moderate Alzheimer's disease (AD); Posiphen(TM)-a potential disease progression treatment for AD now in Phase I; andBisnorcymserine (BNC) - a potential symptomatic treatment of severe ADin the pre-Investigational New Drug (IND) stage.
This press release may contain forward-looking statements orpredictions. These statements represent our judgment to date, and aresubject to risks and uncertainties that could materially affect theCompany, including those risks and uncertainties described in thedocuments Axonyx files from time to time with the SEC, specifically Axonyx's annual report on Form 10-K. Specifically, with respect to ourdrug candidates Phenserine, Posiphen(TM) and Bisnorcymserine, Axonyx cannot assure that: any preclinical studies or clinical trials,whether ongoing or conducted in the future, will prove successful, andif successful, that the results can be replicated; safety and efficacyprofiles of any of its drug candidates will be established, or ifestablished, will remain the same, be better or worse in futureclinical trials, if any; pre-clinical results related to cognition andthe regulation of beta-APP and/or amyloid beta will be substantiatedby ongoing or future clinical trials, if any, or that any of its drugcandidates will be able to improve the signs or symptoms of theirrespective clinical indication or slow the progression of Alzheimer's disease; any of its drug candidates will support an NDA filing, willbe approved by the FDA or its equivalent, or if approved, will provecompetitive in the market; Axonyx will be able to successfullyout-license any of its drug candidates; Axonyx will be able tosuccessfully in-license any additional compounds; or that Axonyx willhave or obtain the necessary financing to support its drug developmentprograms. Axonyx cannot assure that it will be successful with regardto identifying a (sub-) licensing partner for any of its compounds. Axonyx undertakes no obligation to publicly release the result of anyrevisions to such forward-looking statements that may be made toreflect events or circumstances after the date hereof or to reflectthe occurrence of unanticipated events.
About Axonyx
Axonyx Inc. is a U.S.-based biopharmaceutical company engaged inthe acquisition and development of proprietary pharmaceuticalcompounds for the treatment of Central Nervous System disorders. TheCompany currently has three compounds in development for Alzheimer'sdisease; Phenserine - a potential symptomatic and disease progressiontreatment of mild to moderate Alzheimer's disease (AD); Posiphen(TM)-a potential disease progression treatment for AD now in Phase I; andBisnorcymserine (BNC) - a potential symptomatic treatment of severe ADin the pre-Investigational New Drug (IND) stage.
This press release may contain forward-looking statements orpredictions. These statements represent our judgment to date, and aresubject to risks and uncertainties that could materially affect theCompany, including those risks and uncertainties described in thedocuments Axonyx files from time to time with the SEC, specifically Axonyx's annual report on Form 10-K. Specifically, with respect to ourdrug candidates Phenserine, Posiphen(TM) and Bisnorcymserine, Axonyx cannot assure that: any preclinical studies or clinical trials,whether ongoing or conducted in the future, will prove successful, andif successful, that the results can be replicated; safety and efficacyprofiles of any of its drug candidates will be established, or ifestablished, will remain the same, be better or worse in futureclinical trials, if any; pre-clinical results related to cognition andthe regulation of beta-APP and/or amyloid beta will be substantiatedby ongoing or future clinical trials, if any, or that any of its drugcandidates will be able to improve the signs or symptoms of theirrespective clinical indication or slow the progression of Alzheimer's disease; any of its drug candidates will support an NDA filing, willbe approved by the FDA or its equivalent, or if approved, will provecompetitive in the market; Axonyx will be able to successfullyout-license any of its drug candidates; Axonyx will be able tosuccessfully in-license any additional compounds; or that Axonyx willhave or obtain the necessary financing to support its drug developmentprograms. Axonyx cannot assure that it will be successful with regardto identifying a (sub-) licensing partner for any of its compounds. Axonyx undertakes no obligation to publicly release the result of anyrevisions to such forward-looking statements that may be made toreflect events or circumstances after the date hereof or to reflectthe occurrence of unanticipated events.
At Annual General Meeting of Shareholders Neurochem highlights ...Yahoo! News (press release) - USA... 9th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy (Geneva ... of tramiprosate (Alzhemed(TM)) to bind to soluble amyloid (beta) (A(beta ...
posted by Valery Yermalitsky at
6:31 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home